Pekin Hardy Strauss Inc. Has $5.41 Million Holdings in The Chemours Company $CC

Pekin Hardy Strauss Inc. trimmed its holdings in shares of The Chemours Company (NYSE:CC) by 10.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 341,553 shares of the specialty chemicals company’s stock after selling 38,845 shares during the period. Pekin Hardy Strauss Inc.’s holdings in Chemours were worth $5,410,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Public Sector Pension Investment Board lifted its position in shares of Chemours by 14.4% during the 3rd quarter. Public Sector Pension Investment Board now owns 583,947 shares of the specialty chemicals company’s stock valued at $9,250,000 after acquiring an additional 73,635 shares during the period. Oppenheimer & Co. Inc. bought a new stake in Chemours in the third quarter valued at $206,000. Old West Investment Management LLC bought a new stake in Chemours in the third quarter valued at $379,000. Envestnet Asset Management Inc. acquired a new position in shares of Chemours during the third quarter valued at about $243,000. Finally, Hantz Financial Services Inc. boosted its position in shares of Chemours by 334.2% during the 3rd quarter. Hantz Financial Services Inc. now owns 4,329 shares of the specialty chemicals company’s stock worth $69,000 after purchasing an additional 3,332 shares in the last quarter. Institutional investors and hedge funds own 76.26% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Royal Bank Of Canada restated an “outperform” rating and issued a $18.00 target price on shares of Chemours in a research note on Friday, January 16th. Weiss Ratings reissued a “sell (d)” rating on shares of Chemours in a research note on Wednesday, January 21st. Truist Financial upped their target price on Chemours from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, January 21st. UBS Group cut their target price on Chemours from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, November 11th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Chemours from $15.00 to $13.00 and set a “neutral” rating for the company in a research note on Wednesday, December 3rd. Five equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $16.67.

Chemours News Summary

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Q4 EPS beat consensus — Chemours reported $0.05 EPS, beating the Zacks/Street breakeven expectation, which helped limit immediate downside after the print. Read More.
• Positive Sentiment: Increased bullish options activity — unusual call buying volume was reported (roughly 6,344 calls, ~65% above normal), signaling some traders are positioning for upside despite the mixed print.
• Neutral Sentiment: Company provided full‑year revenue range near consensus — management gave FY‑2026 revenue guidance around $6.0–$6.1B (roughly in line with consensus), which reduces uncertainty on top‑line growth but didn’t excite investors. Read More.
• Neutral Sentiment: Market write‑ups and valuation checks circulated after the move — analysts and outlets ran valuation/overview pieces assessing recent share momentum and how the beat fits into the longer story. Read More.
• Negative Sentiment: Operational weakness and cash flow concerns raised by third‑party data — a reported miss on revenue versus some estimates and a sharp drop in gross profit/operating profit (swing to operating loss), plus negative operating cash flow and elevated capex, are big red flags for margins and liquidity. Read More.
• Negative Sentiment: Institutional trimming and mixed analyst views — multiple large funds reduced positions recently and the median analyst target sits below current levels, which can pressure the stock if institutional outflows continue. Read More.
• Negative Sentiment: Balance sheet / margin metrics remain a concern — recent filings show negative net margin and high leverage metrics that increase sensitivity to weaker cash flow and cyclical demand (investors are focusing on margin recovery and deleveraging path). Read More.

Chemours Trading Down 3.5%

NYSE:CC opened at $20.42 on Friday. The Chemours Company has a 52 week low of $9.13 and a 52 week high of $21.85. The firm has a 50-day moving average price of $15.16 and a two-hundred day moving average price of $14.41. The company has a debt-to-equity ratio of 13.66, a quick ratio of 0.88 and a current ratio of 1.71. The firm has a market cap of $3.06 billion, a price-to-earnings ratio of -9.20 and a beta of 1.63.

Chemours (NYSE:CC) last announced its earnings results on Thursday, February 19th. The specialty chemicals company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.04. The firm had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.33 billion. Chemours had a positive return on equity of 35.27% and a negative net margin of 5.70%.The company’s revenue was down 2.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.09 EPS. On average, equities analysts expect that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 13th. Stockholders of record on Friday, February 27th will be given a dividend of $0.0875 per share. The ex-dividend date of this dividend is Friday, February 27th. This represents a $0.35 annualized dividend and a dividend yield of 1.7%. Chemours’s dividend payout ratio (DPR) is currently -15.77%.

Chemours Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.